Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1218

1.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Feb 9;3:17008. doi: 10.1038/nrdp.2017.8. No abstract available.

PMID:
28179635
2.

An integrated approach identifies mediators of local recurrence in Head & Neck Squamous Carcinoma.

Citron F, Armenia J, Franchin G, Polesel J, Talamini R, D'Andrea S, Sulfaro S, Croce CM, Klement W, Otasek D, Pastrello C, Tokar T, Jurisica I, French D, Bomben R, Vaccher E, Serraino D, Belletti B, Vecchione A, Barzan L, Baldassarre G.

Clin Cancer Res. 2017 Feb 7. pii: clincanres.2814.2016. doi: 10.1158/1078-0432.CCR-16-2814. [Epub ahead of print]

PMID:
28174235
3.

MicroRNAs in melanoma development and resistance to target therapy.

Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G.

Oncotarget. 2017 Jan 19. doi: 10.18632/oncotarget.14763. [Epub ahead of print] Review.

4.

RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.

Lee TJ, Yoo JY, Shu D, Li H, Zhang J, Yu JG, Jaime-Ramirez AC, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, Croce CM.

Mol Ther. 2017 Jan 18. pii: S1525-0016(16)45424-9. doi: 10.1016/j.ymthe.2016.11.016. [Epub ahead of print]

PMID:
28109960
5.

Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53.

Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, Adamo A, Krampera M, Scupoli MT, Croce CM, Scarpa A.

Oncotarget. 2017 Jan 17. doi: 10.18632/oncotarget.14683. [Epub ahead of print]

6.

c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity.

Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM, Condorelli G.

Cell Death Differ. 2017 Jan 20. doi: 10.1038/cdd.2017.7. [Epub ahead of print] No abstract available.

PMID:
28106885
7.

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM.

J Exp Med. 2017 Jan 19. pii: jem.2012095001172017c. doi: 10.1084/jem.2012095001172017c. [Epub ahead of print] No abstract available.

PMID:
28104811
8.

Chronic lymphocytic leukaemia.

Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K.

Nat Rev Dis Primers. 2017 Jan 19;3:16096. doi: 10.1038/nrdp.2016.96. Review.

PMID:
28102226
9.

A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.

D'Avino C, Palmieri D, Braddom A, Zanesi N, James C, Cole S, Salvatore F, Croce CM, De Lorenzo C.

Oncotarget. 2016 Dec 27;7(52):87016-87030. doi: 10.18632/oncotarget.13522.

10.

Rab22a controls MHC-I intracellular trafficking and antigen cross-presentation by dendritic cells.

Cebrian I, Croce C, Guerrero NA, Blanchard N, Mayorga LS.

EMBO Rep. 2016 Dec;17(12):1753-1765.

PMID:
27861124
11.

The Fhit protein: an opportunity to overcome chemoresistance.

Gaudio E, Paduano F, Croce CM, Trapasso F.

Aging (Albany NY). 2016 Nov 12;8(11):3147-3150. doi: 10.18632/aging.101123. No abstract available.

12.

ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5.

Sun HL, Cui R, Zhou J, Teng KY, Hsiao YH, Nakanishi K, Fassan M, Luo Z, Shi G, Tili E, Kutay H, Lovat F, Vicentini C, Huang HL, Wang SW, Kim T, Zanesi N, Jeon YJ, Lee TJ, Guh JH, Hung MC, Ghoshal K, Teng CM, Peng Y, Croce CM.

Cancer Cell. 2016 Nov 14;30(5):723-736. doi: 10.1016/j.ccell.2016.10.001.

PMID:
27846390
13.

Regulation of microRNA expression by HMGA1 proteins.

De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Hoyos JM, Forzati F, Croce CM, Fusco A.

Oncogene. 2016 Nov 3;35(44):5817-5818. doi: 10.1038/onc.2016.136. No abstract available.

PMID:
27399337
14.

Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer.

Iorio MV, Croce CM.

Cancer Res. 2016 Nov 1;76(21):6143-6145. No abstract available.

PMID:
27803102
15.

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B.

Clin Cancer Res. 2016 Nov 1;22(21):5265-5276.

PMID:
27390350
16.

Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.

Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang P.

Oncogene. 2016 Oct 27;35(43):5663-5673. doi: 10.1038/onc.2016.103.

17.

MicroRNA-29b mediates altered innate immune development in acute leukemia.

Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, Blum W, Yu J, Freud AG, Caligiuri MA.

J Clin Invest. 2016 Dec 1;126(12):4404-4416. doi: 10.1172/JCI85413.

PMID:
27775550
18.

Retraction: Are circRNAs involved in cancer pathogenesis?

Croce CM.

Nat Rev Clin Oncol. 2016 Nov;13(11):658. doi: 10.1038/nrclinonc.2016.163. No abstract available.

PMID:
27698349
19.

Genetics: Are circRNAs involved in cancer pathogenesis?

Croce CM.

Nat Rev Clin Oncol. 2016 Nov;13(11):658. doi: 10.1038/nrclinonc.2016.113. No abstract available. Retraction in: Nat Rev Clin Oncol. 2016 Nov;13(11):658.

PMID:
27458008
20.

Finally, An Apoptosis-Targeting Therapeutic for Cancer.

Croce CM, Reed JC.

Cancer Res. 2016 Oct 15;76(20):5914-5920. Review.

PMID:
27694602
Items per page

Supplemental Content

Support Center